Baldo et al. suggested a possible relationship between increased cathepsin B activity and cardiovascular symptoms [341], which was subsequently confirmed by Gonzalez et al. using the cathepsin B inhibitor Ca-074 in an MPS I mouse model [342]. This evidence concerns the gene CTSB and Scheie syndrome.